Patient Access 2021

A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.

Our conference has been designed around three core market access areas, each with a specific mission to bring you the latest insights and information for accelerating patient access.

Developments in
strategy and HTA

  • The importance of patient engagement throughout the HTA process

  • Using patient registries in HTAs

  • Appraisal process of medical devices compared with drugs

  • Health economic modelling of digital apps

  • Access to Orphan Medicines: Developing policies for the future

Innovation tools

  • Approaches to utilising Real World Evidence (RWE)

  • Using analytics and big data to gain competitive advantage in Market Access

  • Collaborative working and horizon scanning

  • Harnessing digital systems and technology to find new levels of patient value

Pricing and policy

  • VPAS – what you need to know

  • Updates on The Commercial Framework

  • Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs

  • The NHS Long Term Plan and what this actually means for pharma companies

Who should attend?

This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.

The job functions that will benefit most include:

Heads of Market Access

Country Managers

Health Economists

Commercial Directors

Marketing Directors

Managing Directors

Chief Executives

Medical Directors

Policy Officers/Executives

Policy Advisors

Speakers

Lindsay Weaver

CEO, Metabolic Support UK


The importance of patient engagement throughout the HTA process

David Gillen

Vice President international Medical Affairs, Vertex

Using patient registries in HTAs

Melinda Goodall

Associate Director, NICE


Andi Orlowski

Head of Business Intelligence, Imperial College Healthcare Partners

Approaches to utilising Real World Evidence (RWE)

David Watson

Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)

The Voluntary Scheme; what you need to know

Darren Spevick

Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group 

Harnessing digital systems and technology to find new levels of patient value

Carla Deakin

Programme Director, Commercial & Managed Access, NICE

Sarah Walker

Senior Consultant Policy and Public Affairs, MAP BioPharma

Kate Learoyd

Campaign Manager, NSPKU – National Society for Phenylketonuria

Christian Hill

CEO, MAP BioPharma

 

Exhibitors

NIHRIO_RGB_logo_outlined_COL

We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.

NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.

O4 research

O4 Research is a UK/Ireland based provider of innovative, sector leading clinical trial services and ‘On & Off’ site management solutions. For over a decade we have successfully delivered full and functional services for Top 20 Pharma, biotech and medical device clients across Clinical Phases II-IV and RWE studies. We understand the value of RWE and its role in the development of new healthcare interventions. Our scientific expertise, combined with advances in data acquisition, mean we are ideally placed to help you deliver a bespoke solution for timely and compelling evidence generation. We take the complex and make it simple.

Eucope LOGO-RZ_4c-scaled

EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.

Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.

Agenda

Session One
08:30 – Morning coffee & registration
09:00 – Welcome to Patient Access 2020. Introductions and scene setting – Christian Hill, CEO MAP BioPharma

Developments in strategy and HTA
09:15 – The importance of patient engagement throughout the HTA process – Lindsay Weaver, CEO, Metabolic Support UK

09:45 – Using patient registries in HTAs – David Gillen, Vice President international Medical Affairs, Vertex

10:15 – Appraisal process of medical devices compared with drugs – Melinda Goodall, Associate Director, NICE

Break
10:45 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE

Session Two
11:15 – Access to Orphan Medicines: Developing policies for the future – Sarah Walker, Senior Consultant Policy and Public Affairs, MAP BioPharma

11:45 – Panel Discussion: Led by MAP’s Policy and Public Affairs team, this interactive session will bring together experts to consider challenges with and solutions for the appraisal of medicines for rare diseases.

Panellists will reflect on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicines arrangements. Our panel includes:

Kate Learoyd, Campaign Manager, NSPKU – National Society for Phenylketonuria
Lindsay Weaver, CEO, Metabolic Support UK
Member of Parliament – tbc


Break
12:30 – Lunch & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE

Session Three - Innovation tools
13:30 – Approaches to utilising Real World Evidence (RWE) – Andi Orlowski, Head of Business Intelligence, Imperial College Healthcare Partners

14:00 – Collaborative working and Horizon Scanning – The NHS Long Term Plan and what this actually means for pharma companies
Melinda Goodall, Associate Director, NICE

14:30 – Harnessing digital systems and technology to find new levels of patient value – Darren Spevick, Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group.

Break
15:00 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE

Session Four - Pricing and policy
15:30 – VPAS – what you need to know – David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)

16:00 – Commercial and Managed Access in England – Carla Deakin, Programme Director, Commercial & Managed Access, NICE

16:30 – Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
Outputs from ‘meet the expert’ sessions across Europe in 2020 – Christian Hill, Chief Executive Officer, MAP

17:00 – Conference Close – Networking Drinks Reception

Book now

Terms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2020. MAP BioPharma Limited. All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

+44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281

VAT Group Registration Number GB 292 8576 52